Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06831474 · ClinicalTrials.gov registry record · Phase 1

Excretion of Rivaroxaban in Human Breast Milk

A Phase 1 study of Breastfeeding and Postpartum, sponsored by Thomas Jefferson University.

Recruiting
Registry status
Phase 1
Development phase
10
Enrollment target
1
Study location

NCT06831474: Recruiting Phase 1 study of Breastfeeding and Postpartum, sponsored by Thomas Jefferson University.

NCT06831474 is a Phase 1 study of Breastfeeding and Postpartum that is actively recruiting participants, run by Thomas Jefferson University. The registered enrollment target is 10 participants, below the 597-participant average among 36 other Breastfeeding trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06831474, a Phase 1 study of Breastfeeding and Postpartum, is actively recruiting participants, sponsored by Thomas Jefferson University.

RECRUITING
Registry status
Phase 1
Development phase
10 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to investigate the distribution of rivaroxaban into human milk at both therapeutic and prophylactic doses, and over time with repeated dosing.

Primary Outcome

Time/Concentration profile of rivaroxaban in breast milk prior to intake (0) and 3, 6, 12, 15 and 24 hours following morning dose on day 0-1

Interventions

  • DRUG Rivaroxaban 10 MG Oral Tablet
  • DRUG Rivaroxaban 20 MG Oral Tablet

Study Locations (1)

Pennsylvania

  • Thomas Jefferson University Hospital - Philadelphia

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2025-07
Est. Completion 2026-07-31
Phase Phase 1
Thomas Jefferson University

292 total trials

What NCT06831474 shows while recruiting

NCT06831474 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 597-participant average among 36 other Breastfeeding trials with a reported enrollment target (98% lower).

The record links to 6 conditions, with Breastfeeding appearing as the primary indexed condition, and to 2 interventions - of which Rivaroxaban 10 MG Oral Tablet is the first listed.

NCT06831474 reports a single indexed study location in Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT06831474 about?

NCT06831474 is a clinical study titled "Excretion of Rivaroxaban in Human Breast Milk". The purpose of this study is to investigate the distribution of rivaroxaban into human milk at both therapeutic and prophylactic doses, and over time with repeated dosing.

What is the current status of trial NCT06831474?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2025-07. Estimated completion is 2026-07-31.

What conditions does trial NCT06831474 study?

This clinical trial studies the following conditions: Breastfeeding, Postpartum, Breast Milk Collection, VTE (Venous Thromboembolism), VTE Prophylaxis.

What interventions are being tested in trial NCT06831474?

The interventions under investigation include: Rivaroxaban 10 MG Oral Tablet (DRUG), Rivaroxaban 20 MG Oral Tablet (DRUG).

Who is sponsoring clinical trial NCT06831474?

This trial is sponsored by Thomas Jefferson University, which has 292 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06831474 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breastfeeding

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06831474's enrollment target sits among peer trials

10 37th of 36 the lowest of 36 other Breastfeeding trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Breastfeeding trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00623389 · 10 participants · NA

    Evaluation of an Advanced Lower Extremity Neuroprostheses

  • NCT01241864 · 10 participants · Phase 2

    Islet Transplantation in Type 1 Diabetic Kidney Allograft

  • NCT01293214 · 10 participants · NA

    Vascularized Composite Allotransplantation for Multiple Extremity Amputations

  • NCT01474148 · 10 participants · NA

    A Neuroprosthesis for Seated Posture and Balance

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT06831474, the US trial registry maintained by the National Library of Medicine. NCT06831474 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.